MarketMoodz
Praxis Reassesses Vormatrigine After POWER1 Miss
Praxis Precision Medicines said the pivotal POWER1 trial of vormatrigine did not meet its primary endpoint — change in monthly seizure frequency — prompting the company to pause enrollment in POWER2 and reassess the program. Secondary results and a signal in the 30 mg arm give the team options, but the outcome raises uncertainty around timing and the path to approval.
Key Takeaways
- POWER1 missed its primary endpoint (change in monthly seizure frequency) and did not reach statistical significance, per Benzinga reporting.
- The trial met a secondary endpoint: the 50% responder rate, suggesting a subset of patients benefited.
- The 30 mg higher-dose arm showed an encouraging efficacy signal with low discontinuation and a favorable safety profile.
- Enrollment in the confirmatory POWER2 trial is paused while Praxis considers program modifications, and roughly 90% of vormatrigine-treated patients reportedly transitioned to the open-label extension (OLE).
- Praxis is continuing work on planned launches for relutrigine and ulixacaltamide while it reassesses vormatrigine's development path.
People Involved
- No specific individuals mentioned
Entities Involved
- Praxis Precision Medicines (PRAX)Developer of vormatrigine and sponsor of the POWER1/POWER2 trials
- VormatrigineInvestigational antiseizure candidate evaluated in POWER1/POWER2
- POWER1Pivotal Phase 2/3 trial for focal onset seizures that reportedly missed its primary endpoint
- POWER2Planned confirmatory trial with enrollment paused for reassessment
- RADIANTEarlier study of vormatrigine that showed seizure reduction and tolerability
- RelutriginePraxis pipeline candidate the company is preparing to launch
- UlixacaltamidePraxis pipeline candidate the company is preparing to launch
MarketMoodz Analysis
Missing the primary endpoint in a pivotal study is a clear negative for investors: it increases clinical and regulatory risk, clouds commercialization timelines and can pressure valuation until a clear path forward is announced. The fact that the 50% responder rate was met and that the 30 mg arm showed an efficacy signal gives Praxis tactical choices — for example, submitting additional analyses, redesigning POWER2 with a focus on dose, or targeting a narrower patient population — but any of those options will take time and potentially more capital.
Context matters. Praxis pointed to a highly refractory POWER1 population and prior RADIANT data showed seizure reductions and a generally favorable safety profile for vormatrigine, which helps explain why the company is reassessing rather than abandoning the program. For markets, the immediate watch items are (1) Praxis' formal press release and full POWER1 dataset, (2) the company's decision on POWER2's redesign or restart, and (3) whether the internal timeline for relutrigine and ulixacaltamide launches changes — those assets may become the near-term value drivers if vormatrigine is delayed. Reported premarket weakness was noted after the update; investors should confirm price moves with exchange data and await company disclosures for definitive conclusions.
Source: Original Article